Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 77
Filtrar
Mais filtros

Medicinas Complementares
País/Região como assunto
Tipo de documento
Intervalo de ano de publicação
1.
Sci Rep ; 11(1): 15448, 2021 07 29.
Artigo em Inglês | MEDLINE | ID: mdl-34326377

RESUMO

Herpes simplex virus is among the most prevalent sexually transmitted infections. Acyclovir is a potent, selective inhibitor of herpes viruses and it is indicated for the treatment and management of recurrent cold sores on the lips and face, genital herpes, among other diseases. The problem of the oral bioavailability of acyclovir is limited because of the low permeability across the gastrointestinal membrane. The use of nanoparticles of pseudoboehmite as a drug delivery system in vitro assays is a promising approach to further the permeability of acyclovir release. Here we report the synthesis of high purity pseudoboehmite from aluminium nitrate and ammonium hydroxide containing nanoparticles, using the sol-gel method, as a drug delivery system to improve the systemic bioavailability of acyclovir. The presence of pseudoboehmite nanoparticles were verified by infrared spectroscopy, transmission electron microscopy, and X-ray diffraction techniques. In vivo tests were performed with Wistar rats to compare the release of acyclovir, with and without the addition of pseudoboehmite. The administration of acyclovir with the addition of pseudoboehmite increased the drug content by 4.6 times in the plasma of Wistar rats after 4 h administration. We determined that the toxicity of pseudoboehmite is low up to 10 mg/mL, in gel and the dried pseudoboehmite nanoparticles.


Assuntos
Aciclovir/administração & dosagem , Hidróxido de Alumínio/química , Óxido de Alumínio/química , Antivirais/administração & dosagem , Sistemas de Liberação de Medicamentos/métodos , Nanogéis/química , Aciclovir/sangue , Aciclovir/farmacocinética , Administração Oral , Hidróxido de Alumínio/farmacologia , Óxido de Alumínio/farmacologia , Animais , Antivirais/sangue , Antivirais/farmacocinética , Disponibilidade Biológica , Células CACO-2 , Sobrevivência Celular/efeitos dos fármacos , Liberação Controlada de Fármacos , Herpes Simples/tratamento farmacológico , Herpes Simples/virologia , Humanos , Modelos Animais , Ratos , Ratos Wistar , Simplexvirus/efeitos dos fármacos
2.
AAPS PharmSciTech ; 22(5): 181, 2021 Jun 15.
Artigo em Inglês | MEDLINE | ID: mdl-34129154

RESUMO

In this study, two hydrophilic polymers hydroxypropyl methyl cellulose and beta-cyclodextrin (ß-CD) are used to synthesize highly responsive and spongy polymeric matrices. Porous and stimulus-responsive polymeric network was developed to improve the solubility of acyclovir (ACV) at significant level. Grafting was successfully carried out by free radical polymerization technique. Spongy matrices were characterized by percentage entrapment efficiency, drug loading, solubility studies, FTIR, powder X-ray diffraction, TGA, DSC, XRD, SEM, swelling studies, and in vitro studies. Acute oral toxicity studies were conducted to determine the safety of oral administration of prepared HPMC-ßCD-g-poly(AMPS) formulation. Porous and spongy structures were depicted in SEM images. Complex formation and thermal stability of constituents and drug (ACV) were analyzed by FTIR, TGA, and DSC spectra. XRD analysis revealed reduction in acyclovir crystallinity in spongy matrices. Particle size of optimized formulation was found in the range of 197 ± 2.55 nm. The momentous difference with reference product committed that drug solubility and release characteristics were markedly enhanced by the developed spongy matrices. Toxicity studies endorsed that developed spongy matrices were non-toxic and compatible to biological system. The efficient method of preparation, enhanced solubility, excellent physico-chemical characteristics, high dissolution, and non-toxic HPMC-ßCD-g-poly(AMPS) spongy matrices may be a promising approach for oral delivery of poorly soluble drugs.


Assuntos
Acrilamidas/síntese química , Aciclovir/síntese química , Alcanossulfonatos/síntese química , Derivados da Hipromelose/síntese química , Polimerização , beta-Ciclodextrinas/síntese química , Acrilamidas/administração & dosagem , Aciclovir/administração & dosagem , Administração Oral , Alcanossulfonatos/administração & dosagem , Animais , Antivirais/administração & dosagem , Antivirais/síntese química , Avaliação Pré-Clínica de Medicamentos/métodos , Derivados da Hipromelose/administração & dosagem , Masculino , Tamanho da Partícula , Polímeros/administração & dosagem , Polímeros/síntese química , Coelhos , Solubilidade , Espectroscopia de Infravermelho com Transformada de Fourier/métodos , Difração de Raios X/métodos , beta-Ciclodextrinas/administração & dosagem
3.
Oncol Res Treat ; 43(12): 672-678, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-33070144

RESUMO

INTRODUCTION: We report on patients who developed severe acyclovir-resistant (ACVr) herpes simplex virus 1 (HSV-1) stomatitis after allogeneic hematopoietic cell transplantation (HCT). PATIENTS: HCT patients suffering from HSV-1 stomatitis without response after 1 week of high-dose acyclovir (ACV) were tested for ACV resistance. Patients with proven ACV resistance were treated either topically with cidofovir solution and gel or with topical foscavir cream or with intravenous foscavir. RESULTS: Among 214 consecutive HCT patients, 6 developed severe ACVr HSV-1 stomatitis (WHO grade III n = 1, WHO grade IV n = 5). All 6 patients suffered from relapse of acute myeloid leukemia (AML) after HCT. ACVr stomatitis was treated topically with first-line (n = 4) or second-line (n = 2) cidofovir. Topical foscavir cream was applied as first-line (n = 1) or second-line (n = 1) therapy. Intravenous foscavir was used in 3 patients (first-line therapy, n = 1; second-line therapy, n = 2). Complete remission was reached by topical cidofovir (n = 3), topical foscavir (n = 1), and intravenous foscavir (n = 1), respectively. Five of the 6 patients died due to progression of leukemia. Only 1 patient survived. CONCLUSIONS: ACVr HSV-1 stomatitis is a severe complication in AML patients relapsing after HCT. It reflects the seriously impaired general condition of these patients. This analysis shows that topical treatment with cidofovir or foscavir might be a sufficient first-line therapy approach in ACVr HSV-1 stomatitis. It might serve as a less toxic alternative to intravenous foscavir.


Assuntos
Antivirais/administração & dosagem , Cidofovir/administração & dosagem , Foscarnet/administração & dosagem , Transplante de Células-Tronco Hematopoéticas/efeitos adversos , Herpes Simples/tratamento farmacológico , Estomatite/tratamento farmacológico , Aciclovir/administração & dosagem , Aciclovir/farmacologia , Administração Tópica , Adulto , Idoso , Farmacorresistência Viral/efeitos dos fármacos , Feminino , Transplante de Células-Tronco Hematopoéticas/métodos , Herpes Simples/etiologia , Herpesvirus Humano 1/efeitos dos fármacos , Humanos , Leucemia Mieloide Aguda/complicações , Leucemia Mieloide Aguda/terapia , Masculino , Pessoa de Meia-Idade , Estomatite/virologia , Resultado do Tratamento
4.
AAPS PharmSciTech ; 21(7): 285, 2020 Oct 14.
Artigo em Inglês | MEDLINE | ID: mdl-33057878

RESUMO

Currently, pharmaceutical research is directed wide range for developing new drugs for oral administration to target disease. Acyclovir formulation is having common issues of short half-life and poor permeability, causing messy treatment which results in patient incompliance. The present study formulates a lipid polymeric hybrid nanoparticles for antiviral acyclovir (ACV) agent with Phospholipon® 90G (lecithin), chitosan, and polyethylene glycol (PEG) to improve controlled release of the drugs. The study focused on the encapsulation of the ACV in lipid polymeric particle and their sustained delivery. The formulation developed for the self-assembly of chitosan and lecithin to form a shell encapsulating acyclovir, followed by PEGylation. Optimisation was performed via Box-Behnken Design (BBD), forming nanoparticles with size of 187.7 ± 3.75 nm, 83.81 ± 1.93% drug-entrapped efficiency (EE), and + 37.7 ± 1.16 mV zeta potential. Scanning electron microscopy and transmission electron microscopy images displayed spherical nanoparticles formation. Encapsulation of ACV and complexity with other physical parameters are confirmed through analysis using Fourier transform infrared spectroscopy, differential scanning calorimetry, and X-ray diffraction. Nanoparticle produced was capable of achieving 24-h sustained release in vitro on gastric and intestinal environments. Ex vivo study proved the improvement of acyclovir's apparent permeability from 2 × 10-6 to 6.46 × 10-6 cm s-1. Acyclovir new formulation was achieved to be stable up to 60 days for controlled release of the drugs. Graphical abstract.


Assuntos
Aciclovir/administração & dosagem , Antivirais/administração & dosagem , Aciclovir/farmacocinética , Animais , Antivirais/farmacocinética , Quitosana , Preparações de Ação Retardada , Composição de Medicamentos , Estabilidade de Medicamentos , Absorção Intestinal , Lecitinas , Lipídeos/química , Nanopartículas , Tamanho da Partícula , Polietilenoglicóis , Coelhos
5.
Pharm Nanotechnol ; 7(5): 389-403, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-31465287

RESUMO

BACKGROUND: Acyclovir use is limited by a high frequency of administration of five times a day and low bioavailability. This leads to poor patient compliance. OBJECTIVES: To overcome the problem of frequent dosing, we used nanotechnology platform to evaluate the proof of concept of substituting multiple daily doses of acyclovir with a single dose. METHODS: Acyclovir was formulated as solid lipid nanoparticles (SLN). The nanoparticles were characterized for particle size, surface charge and morphology and in vitro drug release. The pharmacokinetic and pharmacodynamic of SLN acyclovir were compared with conventional acyclovir in a mouse model. RESULTS: SLN showed drug loading of 90.22% with 67.44% encapsulation efficiency. Particle size was found to be of 131 ± 41.41 nm. In vitro drug release showed 100% release in SIF in 7 days. AUC0-∞ (119.43 ± 28.74 µg/ml h), AUMC0-∞ (14469 ± 4261.16 µg/ml h) and MRT (120.10 ± 9.21 h) were significantly higher for ACV SLN as compared to ACV AUC0-∞ (12.22 ± 2.47 µg/ml h), AUMC0-∞ (28.78 ± 30.16 µg/ml h) and MRT (2.07 ± 1.77 h), respectively (p<0.05). In mouse model, a single dose of ACV SLN was found to be equivalent to ACV administered as 400mg TID for 5 days in respect to lesion score and time of healing. CONCLUSION: The proof of concept of sustained-release acyclovir enabling administration as a single dose was thus demonstrated.


Assuntos
Aciclovir/química , Antivirais/química , Herpes Simples/tratamento farmacológico , Lecitinas/química , Fosfolipídeos/química , Aciclovir/administração & dosagem , Aciclovir/farmacologia , Animais , Antivirais/administração & dosagem , Antivirais/farmacologia , Disponibilidade Biológica , Sobrevivência Celular , Modelos Animais de Doenças , Liberação Controlada de Fármacos , Feminino , Haplorrinos , Humanos , Masculino , Camundongos , Camundongos Endogâmicos BALB C , Polissorbatos/química
6.
BMJ Case Rep ; 12(5)2019 May 27.
Artigo em Inglês | MEDLINE | ID: mdl-31138593

RESUMO

A 60-year-old man with a history of severe herpes simplex virus type 1 (HSV-1) encephalitis 2 years prior presented with acute onset of visual loss in the left eye. Dilated funduscopic examination showed retinitis and occlusive vasculitis with retinal necrosis. PCR of the vitreous fluid was positive for HSV-1, and he was diagnosed with acute retinal necrosis (ARN) due to HSV-1. The patient was treated with intravenous acyclovir and intravitreous foscarnet for 2 weeks, followed by high dose oral valacyclovir for 2 weeks. He was subsequently placed on planned life-long suppressive valacyclovir. His case demonstrates that acute visual loss concomitant with or subsequent to HSV-1 encephalitis warrants suspicion of ARN. Prompt therapy with effective antiviral medication is necessary to reduce the risk of sight-threatening complications. Chronic suppression with oral antiviral therapy after ARN is recommended to prevent involvement of the contralateral eye, though there is no consensus on the duration and dosage of antivirals.


Assuntos
Encefalite por Herpes Simples/complicações , Encefalite por Herpes Simples/diagnóstico , Síndrome de Necrose Retiniana Aguda/diagnóstico por imagem , Síndrome de Necrose Retiniana Aguda/etiologia , Doença Aguda , Aciclovir/administração & dosagem , Aciclovir/uso terapêutico , Antivirais/uso terapêutico , Diagnóstico Diferencial , Encefalite por Herpes Simples/virologia , Infecções Oculares Virais/complicações , Infecções Oculares Virais/diagnóstico , Foscarnet/administração & dosagem , Foscarnet/uso terapêutico , Herpesvirus Humano 1/genética , Herpesvirus Humano 1/isolamento & purificação , Humanos , Injeções Intravítreas , Masculino , Pessoa de Meia-Idade , Oftalmoscópios , Doenças Raras , Síndrome de Necrose Retiniana Aguda/tratamento farmacológico , Síndrome de Necrose Retiniana Aguda/virologia , Resultado do Tratamento , Valaciclovir/administração & dosagem , Valaciclovir/uso terapêutico
7.
BMJ Open ; 9(5): e026201, 2019 05 14.
Artigo em Inglês | MEDLINE | ID: mdl-31092654

RESUMO

OBJECTIVE: To compare New Zealand medical grade kanuka honey with topical aciclovir for the treatment of herpes simplex labialis. DESIGN: Prospective parallel randomised controlled open-label superiority trial. SETTING: 76 community pharmacies across New Zealand between 10 September 2015 and 13 December 2017. PARTICIPANTS: 952 adults randomised within the first 72 hours of a herpes simplex labialis episode. INTERVENTIONS: Random assignment 1:1 to either 5% aciclovir cream or medical grade kanuka honey (90%)/glycerine (10%) cream, both applied five times daily. OUTCOME MEASURES: The primary outcome was time from randomisation to return to normal skin (stage 7). Secondary outcomes included time from randomisation to stage 4 (open wound), time from stage 4 to 7, maximal pain, time to pain resolution and treatment acceptability. RESULTS: Primary outcome variable: Kaplan-Meier-based estimates (95% CI) for the median time in days for return to normal skin were 8 (8 to 9) days for aciclovir and 9 (8 to 9) for honey; HR (95% CI) 1.06 (0.92 to 1.22), p=0.56. There were no statistically significant differences between treatments for all secondary outcome variables. No related serious adverse events were reported. CONCLUSION: There was no evidence of a difference in efficacy between topical medical grade kanuka honey and 5% aciclovir in the pharmacy-based treatment of herpes simplex labialis. TRIAL REGISTRATION NUMBER: ACTRN12615000648527;Post-results.


Assuntos
Aciclovir/administração & dosagem , Antivirais/administração & dosagem , Herpes Labial/tratamento farmacológico , Mel , Adulto , Feminino , Humanos , Kunzea , Masculino , Pessoa de Meia-Idade , Nova Zelândia , Farmácias/estatística & dados numéricos , Estudos Prospectivos , Cicatrização/efeitos dos fármacos
8.
J Cosmet Laser Ther ; 21(3): 145-146, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-30019972

RESUMO

Fractional photothermolysis was initially introduced by Manstein in 2004 .Fractional CO2 laser technology introduced has allowed physicians to obtain good cosmetic results with a lower rate of complications than non-fractionated ablative laser treatment. However, adverse effects may still occur.Reported cases of HSV infection after fractional photothermolysis are rare. A 48-year-old woman with Fitzpatrick skin type III presented with a scar in her perioral area desiring esthetic improvement of her burn scar. She didn't have a history of recurrent herpes simplex virus (HSV) infection periorally. A fractionated resurfacing laser Quadralase (Candela) was used to treat her perioral burn scar. Two sessions were performed with a month interval. Five days after the second session of laser therapy even after she took antiviral prophylaxis based on valacyclovir 500mg twice daily 24 hours before the laser session and 3 days after, she presented with a rash on the perioral area preceded by pain. Correlation of the history and the clinical presentation was consistent with HSV reactivation. Treatment was initiated with acyclovir 10mg/kg/8h administered intravenously for 10 days with a clearing of her vesicular eruption. Fractional CO2 laser is a very safe procedure when used with accepted parameters. Early recognition, close monitoring and careful wound care will prevent long term sequelae when complications occur.


Assuntos
Queimaduras/complicações , Cicatriz/radioterapia , Herpes Simples/etiologia , Lasers de Gás/efeitos adversos , Terapia com Luz de Baixa Intensidade/efeitos adversos , Simplexvirus/efeitos da radiação , Ativação Viral/efeitos da radiação , Aciclovir/administração & dosagem , Aciclovir/uso terapêutico , Administração Intravenosa , Antibioticoprofilaxia , Antivirais/administração & dosagem , Antivirais/uso terapêutico , Cicatriz/etiologia , Fracionamento da Dose de Radiação , Feminino , Seguimentos , Herpes Simples/tratamento farmacológico , Humanos , Lasers de Gás/uso terapêutico , Pessoa de Meia-Idade , Boca/patologia , Simplexvirus/fisiologia , Resultado do Tratamento
9.
Life Sci ; 215: 80-85, 2018 Dec 15.
Artigo em Inglês | MEDLINE | ID: mdl-30403989

RESUMO

AIMS AND METHODS: Many antiviral agents have been reported to present direct cytotoxic activity in cancer, showing antiproliferative and proapoptotic effects through different mechanisms. In the present study, we took into account the cytotoxic action of the antiviral drug acyclovir (ACV) on leukemia cells, by investigating cell cycle perturbations and apoptosis induction upon drug administration to three still unexplored cell lines, namely Jurkat, U937, and K562. At the same time, the cytotoxicity of cisplatin (CDDP) and 5­fluorouracil (5­FU) in combination with ACV was assessed, thus to evaluate if the antiviral agent could enhance cancer cell sensitivity to these chemotherapeutic drugs. FINDINGS AND SIGNIFICANCE: Our results showed that ACV cytotoxic action was maximum in Jurkat cells (acute T cell leukemia), which showed a dose- and time-dependent reduction of cell viability after drug exposure. The flow cytometric analysis of cell cycle revealed a delay/block in S phase and an increase of the sub-G1 peak upon ACV administration, thereby indicating apoptotic cell death. The activation of caspase-3 and the presence of nuclear DNA fragmentation confirmed the induction of apoptosis in ACV-treated cells. Interestingly, the pre-treatment of Jurkat cells with ACV for 72 h or 7 days increased CDDP and 5-FU cytotoxicity, suggesting enhanced leukemia cell sensitivity to these anticancer drugs.


Assuntos
Aciclovir/farmacologia , Protocolos de Quimioterapia Combinada Antineoplásica/farmacologia , Cisplatino/farmacologia , Fluoruracila/farmacologia , Leucemia/tratamento farmacológico , Aciclovir/administração & dosagem , Antineoplásicos/administração & dosagem , Antineoplásicos/farmacologia , Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem , Antivirais/administração & dosagem , Antivirais/farmacologia , Apoptose/efeitos dos fármacos , Ciclo Celular/efeitos dos fármacos , Sobrevivência Celular/efeitos dos fármacos , Cisplatino/administração & dosagem , Fragmentação do DNA/efeitos dos fármacos , Relação Dose-Resposta a Droga , Citometria de Fluxo , Fluoruracila/administração & dosagem , Humanos , Células Jurkat , Células K562 , Leucemia/patologia , Fatores de Tempo , Células U937
10.
BMC Nephrol ; 19(1): 324, 2018 11 14.
Artigo em Inglês | MEDLINE | ID: mdl-30428841

RESUMO

BACKGROUND: Acyclovir is one of the most common prescribed antiviral drugs. Acyclovir nephrotoxicity occurs in approximately 12-48% of cases. It can present in clinical practice as acute kidney injury (AKI), crystal-induced nephropathy, acute tubulointerstitial nephritis, and rarely, as tubular dysfunction. Electrolytes abnormalities like hypokalemia, were previously described only when given intravenously. CASE PRESENTATION: A 54 year-old female presented with weakness and lower extremities paresis, nausea and vomiting after receiving oral acyclovir. Physical examination disclosed a decrease in the patellar osteotendinous reflexes (++ / ++++). Laboratory data showed a serum creatinine level of 2.1 mg/dL; serum potassium 2.1 mmol/L. Kidney biopsy was obtained; histological findings were consistent with acute tubular necrosis and acute tubulointerstitial nephritis. The patient was advised to stop the medications and to start with oral and intravenous potassium supplement, symptoms improved and continued until serum potassium levels were > 3.5 meq/L. CONCLUSIONS: The case reported in this vignette is unique since it is the first one to describe hypokalemia associated to acute tubular necrosis induced by oral acyclovir.


Assuntos
Aciclovir/efeitos adversos , Antivirais/efeitos adversos , Hipopotassemia/induzido quimicamente , Hipopotassemia/patologia , Necrose Tubular Aguda/induzido quimicamente , Necrose Tubular Aguda/patologia , Aciclovir/administração & dosagem , Administração Oral , Antivirais/administração & dosagem , Feminino , Humanos , Hipopotassemia/sangue , Necrose Tubular Aguda/sangue , Pessoa de Meia-Idade
11.
Eur J Pharm Sci ; 121: 228-235, 2018 08 30.
Artigo em Inglês | MEDLINE | ID: mdl-29778782

RESUMO

The study aimed to develop a patient-friendly acyclovir gel with improved efficacy in viral mouth infections, in response to patients' need for an intraoral acyclovir product. Acyclovir was loaded in lipid nanocapsules in gel form, and formulae were evaluated for oromucosal delivery. Lipid nanocapsules were prepared by the phase inversion method. Formulae were optimized to achieve maximum acyclovir entrapment and minimum acyclovir precipitation. Colloidal properties, and pharmaceutical performance indicators were assessed. Drug-loaded lipid nanocapsules were in the nanorange (39-120 nm), PdI (0.03-0.2), negative zeta potential, and entrapment efficiency (33-64%). Acyclovir (0.3% w/w) lipid nanocapsules gels were prepared using hydroxyethylcellulose (3% w/w). Resulting gel attributes were considered suitable. Lipid nanocapsules gels (0.3% w/w) showed enhanced Ex vivo acyclovir permeation across, and comparable retention in chicken pouch membrane compared to the 5% marketed cream despite lower drug content. The data provides basis for future exploration of lipid nanocapsules as carrier for transmucosal delivery of acyclovir; the enhanced acyclovir retention in chicken pouch membrane, compared to controls, suggests suitability of lipid nanocapsules for drug delivery to the viral lesion within the buccal membrane.


Assuntos
Aciclovir/administração & dosagem , Antivirais/administração & dosagem , Lipídeos/administração & dosagem , Mucosa Bucal/metabolismo , Nanocápsulas/administração & dosagem , Aciclovir/química , Administração Oral , Animais , Antivirais/química , Galinhas , Avaliação Pré-Clínica de Medicamentos , Liberação Controlada de Fármacos , Géis , Lipídeos/química , Nanocápsulas/química
12.
Zhong Nan Da Xue Xue Bao Yi Xue Ban ; 43(2): 168-172, 2018 Feb 28.
Artigo em Chinês | MEDLINE | ID: mdl-29559601

RESUMO

OBJECTIVE: To observe the clinical efficacy and safety of topical ozone therapy for patients with herpes zoster by reflectance confocal microscopy (RCM).
 Methods: A total of 60 patients with herpes zoster were divided into a control group and an ozone treatment group (n=30). In the control group, patients took oral valacyclovir tablets or granules (0.3 g per day, three times a day) and they were subjected to local weak laser irradiation treatment plus topical 2% mupirocin ointment twice a day. In the ozone group, the treatment is same as the control group except mupirocin ointment was replaced with topical ozone treatment (hydrotherapy every day plus ozonated oil twice a day). The clinical symptoms, discoid cell and adverse reactions were observed and taken records at day 0, 3, 7 and 14. Statistical analysis was performed to compare the clinical efficacy between the 2 groups. 
 Results: On the seventh day of treatment, the discoid cells of the ozone group disappeared, and the difference between the control group and the ozone group was statistically significant (P<0.05). The difference of decreased percentage of pain scores at each time point between the 2 groups was statistically significant (P<0.05). The clinical efficacy was 100% in the ozone group and 86.7% in the control group, with significant difference between the 2 groups (P<0.05).
 Conclusion: Topical ozone therapy in patients with herpes zoster is helpful in relieving pain, shortening the course as well as improving the clinical efficacy without obvious adverse reactions. It is worth to be popularized.


Assuntos
Antivirais/administração & dosagem , Herpes Zoster/terapia , Hidroterapia/métodos , Óleos/administração & dosagem , Ozônio/administração & dosagem , Aciclovir/administração & dosagem , Aciclovir/análogos & derivados , Administração Oral , Administração Tópica , Estudos de Casos e Controles , Terapia Combinada/métodos , Esquema de Medicação , Herpes Zoster/complicações , Humanos , Terapia com Luz de Baixa Intensidade , Microscopia Confocal , Mupirocina/administração & dosagem , Manejo da Dor/métodos , Medição da Dor , Resultado do Tratamento , Valaciclovir , Valina/administração & dosagem , Valina/análogos & derivados
13.
Ann Dermatol Venereol ; 145(3): 182-186, 2018 Mar.
Artigo em Francês | MEDLINE | ID: mdl-29221652

RESUMO

BACKGROUND: Chronic HSV infection is a cause of chronic perineal ulcerations. We report a case of a chronic and refractory HSV infection revealing chronic lymphoid leukaemia. PATIENTS AND METHODS: An 85-year-old woman with an 8-month history of chronic perineal ulcerations was referred to our dermatology department. She had no previous medical history of herpes infection. Skin biopsies ruled out carcinoma but were consistent with HSV infection. A local swab was positive for HSV2. Treatment with valaciclovir and intravenous acyclovir (ACV) at the recommended doses was ineffective. Laboratory tests revealed type-B chronic lymphoid leukaemia. Molecular biology studies confirmed the presence of ACV-resistant HSV via decreased thymidine kinase activity (stop codon: M183stop). Foscarnet was administered for a period of 3 weeks with almost complete healing of the ulcerations. Treatment was stopped prematurely due to acute renal insufficiency and the remaining lesions were treated using imiquimod cream. Valaciclovir was prescribed to prevent further episodes. The condition recurred a mere 11 months later. DISCUSSION: The prevalence of ACV-resistant HSV is 0.32 % in immunocompetent patients and 3.5 % in immunocompromised patients. Insufficient dosing regimens or prolonged treatment with TK inhibitors result in the local selection of pre-existing mutant HSV viruses. Foscarnet, a DNA polymerase inhibitor, is the treatment of choice in HSV-resistant infections. ACV-resistant HSV is less virulent and replicates less, with reactivations being mainly due to wild-type HSV latent in the neural ganglia. Valaciclovir can be used as a preventive treatment. To our knowledge, this is the first case of ACV-resistant HSV infection revealing chronic lymphoid leukaemia. CONCLUSION: Chronic perineal ulcerations can be the first manifestation of immunodeficiency seen for example with haematological diseases. In the event of clinical resistance of an HSV infection to recommended thymidine kinase inhibitor regimens, the use of foscarnet should be considered.


Assuntos
Aciclovir , Antivirais , Foscarnet/uso terapêutico , Herpes Simples/complicações , Hospedeiro Imunocomprometido , Leucemia Linfocítica Crônica de Células B/tratamento farmacológico , Aciclovir/administração & dosagem , Adjuvantes Imunológicos/administração & dosagem , Administração Cutânea , Idoso de 80 Anos ou mais , Aminoquinolinas/administração & dosagem , Antivirais/administração & dosagem , Feminino , Herpes Simples/tratamento farmacológico , Humanos , Imiquimode , Períneo/patologia , Períneo/virologia
15.
J Drugs Dermatol ; 16(3): s49-s53, 2017 Mar 01.
Artigo em Inglês | MEDLINE | ID: mdl-28301628

RESUMO

Herpes labialis remains a common worldwide affliction. Recent advances in understanding the basic pathogenesis have led to new therapeutic intervention, both on-label and off-label. Aside from reducing the duration and symptomatology of acute outbreaks, another goal of treatment is to decrease the frequency of future episodes. Oral and topical acyclovir and its analogues are the mainstay of both chronic suppressive and episodic therapy. A new muco-adhesive formulation of acyclovir provides a decrease in outbreaks, probably due to a diminution of herpesvirus load in all reservoir sites. Acyclovir-resistant strains are rare in immunocompetent hosts; parenteral foscarnet and cidofovir are administered in this situation. Parenteral acyclovir is the drug of choice for eczema herpeticum, which may begin as herpes labialis in an atopic dermatitis patient. Thermotherapy may be beneficial, and a certified device to deliver heat is available outside the United States.

J Drugs Dermatol. 2017;16(3 Suppl):s49-53.

.


Assuntos
Antivirais/administração & dosagem , Antivirais/uso terapêutico , Herpes Labial/terapia , Herpesvirus Humano 1/efeitos dos fármacos , Estomatite Herpética/terapia , Carga Viral/efeitos dos fármacos , Aciclovir/administração & dosagem , Aciclovir/uso terapêutico , Administração Oral , Administração Tópica , Adulto , Doença Crônica/terapia , Cidofovir , Citosina/administração & dosagem , Citosina/análogos & derivados , Citosina/uso terapêutico , Farmacorresistência Viral , Foscarnet/administração & dosagem , Foscarnet/uso terapêutico , Herpes Labial/complicações , Herpesvirus Humano 1/isolamento & purificação , Herpesvirus Humano 1/fisiologia , Humanos , Hipertermia Induzida , Infusões Parenterais , Organofosfonatos/administração & dosagem , Organofosfonatos/uso terapêutico , Recidiva , Estomatite Herpética/complicações
16.
J Liposome Res ; 27(4): 283-292, 2017 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-27558522

RESUMO

Niosomes suggest a versatile vesicle delivery system with possible transport of drugs via topical route for skin delivery. The aim of the present research was to optimize niosome gel formulation of acyclovir and to evaluate in both in vitro and in vivo rabbit model. Niosome formulations were formulated by coacervation phase separation technique with different ratios of nonionic surfactants, phospholipids and cholesterol using 32 factorial design. Altering the surfactant concentration has influenced the drug entrapment, but not vesicle size. At high surfactant combinations, the acyclovir release from niosomes was strongly influenced by cholesterol:lecithin ratio. Ex vivo drug permeation data indicate substantial difference in flux values and was influenced by the niosome composition. Ex vivo studies using formulation (B8) for drug deposition indicate greater amount of niosome being diffused into the skin layers and formed a depot, compared to commercial acyclovir cream (control). Two distinct dermatopharmacokinetic profiles were observed, in vivo, for niosome gel formulation (B8) and control, which were analog to the profiles observed with ex vivo deposition studies. In vivo plasma drug level suggests low systemic exposure of acyclovir (Cmax: 9.44 ± 2.27 ng/mL and 14.54 ± 3.11 ng/mL for niosome formulation and control, respectively). Comparison of kinetic data of acyclovir in the stratum corneum and plasma signifies that the niosome formulation forms a depot in the epidermis or dermis region. This study concludes that the niosome gel formulation (B8) could be a viable vesicular system for an impressive transdermal delivery of acyclovir by topical application.


Assuntos
Aciclovir/química , Aciclovir/farmacocinética , Lipossomos/química , Dermatopatias/tratamento farmacológico , Aciclovir/administração & dosagem , Aciclovir/sangue , Administração Cutânea , Animais , Química Farmacêutica/métodos , Colesterol/química , Portadores de Fármacos/química , Liberação Controlada de Fármacos , Estabilidade de Medicamentos , Humanos , Lecitinas/química , Limite de Detecção , Nanopartículas/química , Tamanho da Partícula , Coelhos , Absorção Cutânea , Propriedades de Superfície
17.
Tunis Med ; 95(1): 19-22, 2017 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-29327764

RESUMO

Idiopathic or Bell's palsy is an acute peripheral-nerve palsy involving the facial nerve. The disorder is quite infrequent under the age of 10 years. The proposed etiologies of Bell's palsy include ischemic neuropathy and vascular diseases. This case series presents five children with Bell's palsy. The epidemiologic, diagnostic and therapeutic measures were summarized. The evolution regarding especially the facial motricity was detailed. The results about the role of some thrombophilic polymorphisms suggest a probable involvement of factor V haplotype, MTHFR and factor XIII in the etiology of Bell's palsy in five Tunisian children.


Assuntos
Paralisia de Bell/diagnóstico , Paralisia de Bell/terapia , Aciclovir/administração & dosagem , Substituição de Aminoácidos/genética , Paralisia de Bell/genética , Criança , Pré-Escolar , Estudos de Coortes , Análise Mutacional de DNA , Fator V/genética , Fator XIII/genética , Feminino , Humanos , Hidrocortisona/administração & dosagem , Lactente , Masculino , Metilenotetra-Hidrofolato Redutase (NADPH2)/genética , Manipulações Musculoesqueléticas/métodos , Polimorfismo de Nucleotídeo Único , Indução de Remissão , Trombofilia/complicações , Trombofilia/genética
18.
J Microencapsul ; 32(6): 521-32, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-26333938

RESUMO

The aim of our study was to improve the bioavailability of acyclovir (ACV) by delivery of mucoadhesive nanoparticles (NPs) and controlled delivery of drug at its absorption window. Central composite design was used by which the effects of independent variables (gelatin and Pluronic F-68) on various responses such as particle size, polydispersity index, entrapment efficiency, loading efficiency, drug release and mucoadhesive strength were studied. The optimised formulation was evaluated for morphology, stability, pharmacokinetic and gastrointestinal tracking. The optimised NPs were found to be nearly spherical. Changes in characteristics of NPs were not significant after six months of accelerated stability studies. In vivo mucoadhesion study showed significant retention of mucoadhesive NPs in upper gastro-intestinal tract for more than 12 h. Pharmacokinetic study in rats revealed that mucoadhesive NPs could maintain relatively steady plasma concentration of ACV for more than 10 h. The AUC0-∞ and mean residence time of optimised formulation (7527.9 ng h/mL and 12.09 h) were significantly high than tablet dispersion (3841.13 ng h/mL and 7.97 h).


Assuntos
Aciclovir/administração & dosagem , Portadores de Fármacos , Nanopartículas/química , Administração Oral , Animais , Antivirais/administração & dosagem , Área Sob a Curva , Disponibilidade Biológica , Preparações de Ação Retardada , Sistemas de Liberação de Medicamentos , Avaliação Pré-Clínica de Medicamentos , Gelatina/química , Masculino , Nanomedicina/métodos , Tamanho da Partícula , Poloxâmero/química , Ratos , Ratos Wistar , Comprimidos
20.
Zhongguo Zhen Jiu ; 35(2): 145-8, 2015 Feb.
Artigo em Chinês | MEDLINE | ID: mdl-25854021

RESUMO

OBJECTIVE: To observe the effect of electroacupuncture (EA) combined with ultraviolet therapy on herpes zoster at the acute stage and the impacts on serum interleukin 2 (IL-2), interleukin 6 (IL-6) and interleukin 10 (IL-10) in the patients. METHODS: Thirty-four patients of herpes zoster were randomized into a medicine group and a combined therapy group, 17 cases in each one. In the medicine group, the intravenous drops with acyclovir injection, muscular injection with cobamamide and the topical with acyclovir ointment were applied. Additionally, TDP was radiated locally. In the combined therapy group, on the basis of the treatment as the medicine group, EA and ultraviolet therapy were supplemented. The duration of treatment was 10 days in the two groups. Before and after treatment, blister relief, incrustation time and the visible analogue scale (VAS) were recorded in the two groups. The clinical efficacy was assessed in the two groups and the levels of serum IL-2, IL-6 and IL-10 were determined in the two groups. RESULTS: In the combined therapy group, the time of blister relief and incrustation was earlier apparently than that in the medicine group (both P<0.05). VAS score after treatment were reduced as compared with that before treatment in the two groups (both P<0.01), and the reducing amplitude in the combined therapy group was larger than that in the medicine group (P<0.01). The total effective rate was 94. 1% (16/17) in the combined therapy group, higher than 76.4% (13/17) in the medicine group (P<0.05). After treatment, IL-2 levels were increased as compared with those before treatment in the two groups (both P<0.05), the levels of IL-6 and IL-10 were reduced obviously as compared with those before treatment in the two groups (all P<0.01). After treatment, the levels of IL-6, IL-10 were reduced much more apparently in the combined therapy group as compared with those in the medicine group (both P<0.05). CONCLUSION: EA combined with ultraviolet irradiation more rapidly and effectively relief the symptoms of herpes zoster, significantly relief pain, shorten the duration of sickness, improve the body immunity and reduce nerve injury.


Assuntos
Aciclovir/administração & dosagem , Eletroacupuntura , Herpes Zoster/terapia , Interleucina-10/sangue , Interleucina-2/sangue , Interleucina-6/sangue , Terapia Ultravioleta , Adulto , Terapia Combinada , Feminino , Herpes Zoster/sangue , Herpes Zoster/tratamento farmacológico , Humanos , Masculino , Pessoa de Meia-Idade , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA